Spinraza Slows Lung Decline in SMA Patients

Research indicates that the medication Spinraza is effective in slowing the decline of lung function in patients with spinal muscular atrophy (SMA) who are already exhibiting symptoms. According to a report published by SMA News Today on May 22, 2026, the treatment helps stabilize respiratory capacity, which is a critical factor in the long-term management of the disease.

Spinal muscular atrophy is a genetic disorder characterized by the loss of motor neurons in the spinal cord, leading to progressive muscle wasting and weakness. Because the disease affects the muscles responsible for breathing, including the diaphragm and intercostal muscles, respiratory failure is a primary concern for those living with SMA.

Mechanism of Spinraza in SMA Treatment

Spinraza, known generically as nusinersen, is an antisense oligonucleotide designed to address the underlying genetic cause of SMA. The disease is caused by a deficiency in the survival motor neuron (SMN) protein, which is essential for the survival of motor neurons.

While most SMA patients have a mutation in the SMN1 gene, they typically possess a nearly identical backup gene called SMN2. However, SMN2 does not produce enough functional protein on its own. Spinraza works by modifying the splicing of the SMN2 gene, enabling it to produce a higher amount of full-length, functional SMN protein.

By increasing the levels of this protein, the medication aims to preserve existing motor neurons and prevent further degeneration of the muscles they control, including those essential for pulmonary function.

Impact on Respiratory Decline

For patients who are already symptomatic, the goal of treatment often shifts from preventing the onset of symptoms to stabilizing the disease and slowing the progression of disability. The findings reported on May 22, 2026, highlight the drug’s ability to mitigate the loss of lung capacity in this specific patient population.

Lung function in SMA is typically measured by forced vital capacity (FVC), which tracks the maximum amount of air a person can exhale after taking a deep breath. In untreated symptomatic SMA, FVC typically declines over time as respiratory muscles weaken.

The observed slowing of this decline is significant because it can reduce the frequency of respiratory infections and potentially delay or reduce the reliance on permanent mechanical ventilation. Stabilizing lung function is considered a key objective in improving the overall quality of life and increasing the life expectancy of patients with SMA.

Clinical Context and Patient Management

While the stabilization of lung function is a positive development, medical literature emphasizes that the efficacy of SMA treatments can vary based on the type of SMA and the timing of the intervention. The most profound gains are often seen in infants treated before the onset of significant symptoms.

For those who have already progressed to a symptomatic stage, the slowing of decline represents a shift toward maintenance and the preservation of current capabilities. This suggests that the therapeutic window for nusinersen extends to patients who have already experienced some loss of motor and respiratory function.

Respiratory care for SMA patients remains a multidisciplinary effort. Even with the use of disease-modifying therapies like Spinraza, clinicians typically continue to employ supportive measures, such as:

• Regular monitoring of pulmonary function tests.
• The use of non-invasive ventilation (NIV) to support breathing during sleep or periods of illness.
• Airway clearance techniques to prevent the buildup of mucus in the lungs.
• Coordinated care between neurologists, pulmonologists and physical therapists.

The data regarding the slowing of lung decline provides a basis for ongoing discussions regarding long-term treatment strategies for symptomatic adults and children with SMA, emphasizing the importance of continuous protein supplementation to maintain respiratory stability.